Regulatory issues in cell-based therapy for clinical purposes

Developments in Ophthalmology

Volumn 53, Issue , 2014, Pages 189-200

  Casaroli Marano, Ricardo P ^a,b,c   Tabera, Jaime ^b   Vilarrodona, Anna ^b   Trias, Esteve ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c Instituto Condal de Oftalmologia   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; BIOLOGICAL THERAPY; HUMAN; MEDICAL RESEARCH; MEDICOLEGAL ASPECT; PROCEDURES; RETINAL DISEASES; STANDARDS;

ANIMALS; BIOMEDICAL RESEARCH; CELL- AND TISSUE-BASED THERAPY; HUMANS; LEGISLATION, MEDICAL; RETINAL DISEASES;

EID: 84922284496     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000357766     Document Type: Article

References (19)

1. Di Iorio E, Ferrari S, Fasolo A, Böhm E, Ponzin D, Barbaro V: Techniques for culture and assessment of limbal stem cell grafts. Ocul Surf 2010; 8: 146-153.
2. McMahon AD, Conway DI, Macdonald TM, McInnes GT: The unintended consequences of clinical trials regulations. PLoS Med 2009; 3:e1000131.
3. Thirumala S, Goebel W, Woods EJ: Manufacturing and banking of mesenchymal stem cells. Expert Opin Biol Ther 2013; 13: 673-691.
4. Thirumala S, Goebel WS, Woods EJ: Clinical grade adult stem cell banking. Organogenesis 2009; 5: 143-154.
5. Carpenter MK, Frey-Vasconcells J, Rao MS: Developing safe therapies from human pluripotent stem cells. Nat Biotechnol 2009; 27: 606-613.
6. Polchow B, Kebbel K, Schmiedeknecht G, Reichardt A, Henrich W, Hetzer R, Lueders C: Cryopreservation of human vascular umbilical cord cells under good manufacturing practice conditions for future cell banks. J Transl Med 2012; 10: 98.
7. Carpenter MK, Couture LA: Regulatory considerations for the development of autologous induced pluripotent stem cell therapies. Regen Med 2010; 5: 569-579.
8. Ilic N, Savic S, Siegel E, Atkinson K, Tasic L: Examination of the regulatory frameworks applicable to biologic drugs (including stem cells and their progeny) in Europe, the U.S., and Australia. I. A method of manual documentary analysis. Stem Cells Transl Med 2012; 1: 898-908.
9. Ilic N, Savic S, Siegel E, Atkinson K, Tasic L: Examination of the regulatory frameworks applicable to biologic drugs (including stem cells and their progeny) in Europe, the U.S., and Australia. II. A method of software documentary analysis. Stem Cells Transl Med 2012; 1: 909-920.
10. Ancans J: Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development. Front Immunol 2012; 3: 253.
11. European Medicines Agency, CAT Secretariat & US Food and Drug Administration. Regen Med 2011; 6(suppl): 90-96.
12. Astori G, Soncin S, Lo Cicero V, Siclari F, Sürder D, Turchetto L, Soldati G, Moccetti T: Bone marrow derived stem cells in regenerative medicine as advanced therapy medicinal products. Am J Transl Res 2010; 2: 285-295.
13. Proposed approach to regulation of cellular and tissue-based products. The Food and Drug Administration. 1997. http://www.fda.gov/downloads/ BiologicsBloodVaccines/ Guidance ComplianceRegulatoryInformation/ Guidances/Tissue/UCM062601.pdf.
14. Dietz AB, Padley DJ, Gastineau DA: Infrastructure development for human cell therapy translation. Clin Pharmacol Ther 2007; 82: 320-324.
15. Guidance for Industry: Regulation of human cells, tissues, and cellular and tissue-based products (HCT/Ps)-small entity compliance guide. The Food and Drug Administration. 2007. http://www. fda.gov/BiologicsBloodVaccines/ Guidan ceComplianceRegulatoryInformation/ Guidances/Tissue/ucm073366.pdf.
16. Reflection paper on classification of advanced therapy medicinal products. Committee for Advanced Therapies. European Medicines Agency. 2012. http://www.ema.europa.eu/docs/en GB/document-library/Regulatory-and procedural-guideline/2012/04/ WC500126681.pdf.
17. Guide to safety and quality assurance for organs, tissues and cells. Strasbourg, Council of Europe Publishing, ed 2. 2004. http://www.coe.int/t/dg3/health/ Source/GuideSecurity2-en.pdf.
18. Guideline on human cell-based medicinal products. Committee for Medicinal Product for Human Use. European Medicines Agency. 2008. http://www. ema.europa.eu/docs/en-GB/document library/Scientific-guideline/2009/09/ WC500003894.pdf.
19. Good manufacturing practice (GMP) Guidelines. The rules governing medicinal products in the European Union. EudraLex, vol 4, 2011. http://ec.europa. eu/health/documents/eudralex/vol-4/ index-en.htm.